Neurodevelopmental outcomes in two cases of artemis deficiency
Abstract
Background: Severe Combined Immunodeficiency (SCID) is a category of inborn errors of immunity where there is impaired T and B cell development and/or function. Artemis SCID (Art-SCID) is characterized by dysfunctional Artemis protein, which is crucial for V(D)J recombination in T and B cell maturation. Art-SCID is fatal without management, and current definitive treatment involves hematopoietic stem cell transplantation (HSCT) or gene therapy. As the prognosis and survival of SCID patients improves, current research has begun unveiling long-term complications and morbidities. Previous literature has reported neurodevelopmental abnormalities in SCID patients, such as developmental delay and Autism Spectrum Disorder (ASD). However, it remains unknown whether these neurodevelopmental differences are linked to the SCID mutation, an adverse outcome of treatment and hospitalization, or comorbid social isolation and psychosocial challenges.
Aims: In this case series, we discuss two cases of Art-SCID which presented with neurodevelopmental deficits following successful HSCT.
Results: In both cases, SCID was detected on Newborn Screening (NBS), and Art-SCID was confirmed with genetic testing. Both patients were successfully treated with HSCT at 80 days of life, and followed up clinically well, with robust cell counts. Both patients later presented in toddlerhood with developmental, speech and language delay, however only one patient met diagnostic criteria for ASD.
Conclusion: The definitive relationship between SCID, HSCT, and neurodevelopmental outcomes remain unclear, and warrants further study to allow for early intervention. We are currently working with colleagues across the country to further investigate and define this complex relationship.
Statement of Novelty: We are investigating the complex relationship between SCID, HSCT, and potential neurodevelopmental outcomes. We present two cases of patients with Artemis SCID who were successfully treated with HSCT, and later presented in toddlerhood with developmental, speech, and language delay.
Get full access to this article
View all available purchase options and get full access to this article.
REFERENCES
Puck J.M. (2019). Newborn screening for severe combined immunodeficiency and T-cell lymphopenia. Immunol. Rev. 287(1): 241–252.
Cowan M.J., Yu J., Facchino J., Fraser-Browne C., Sanford U., Kawahara M., Dara J., Long-Boyle J., Oh J., Chan W., Chag S., Broderick L., Chellapandian D., Decaluwe H., Golski C., Hu D., Kuo C.Y., Miller H.K., Petrovic A., Currier R., Hilton J.F., Punwani D., Dvorak C.C., Malech H.L., McIvor R.S., and Puck J.M. (2022). Lentiviral gene therapy for artemis-deficient SCID. New England J. Med. 387(25): 2344–2355.
Quinn J., Orange J.S., Modell V., and Modell F. (2020). The case for severe combined immunodeficiency (SCID) and T cell lymphopenia newborn screening: saving lives… one at a time. Immunol. Res. 68: 48–53.
Eissa H., Thakar M.S., Shah A.J., Buckley R. H., Logan B., Griffith L.M., Dong H., O’Reilly R.J., Kapoor N., Satter L.F., Chandra S., Bleesing J.J., Kapadia M., Parrott R.E., Chandrakasan S., Bednarski J.J. II, Jyonouchi S., Madden L.M., Rayes A., Ebens C., Teira P., Saldaña B.J.D., Burroughs L.M., Prockop S.E., Williams O., Chellapandian D., Gillio A.P., Goldman F., Malech H.L., DeSantes K., Cuvelier G.D.E., Rozmus J., Quinones R., Yu L.C., Broglie L., Aquino V., Shereck E., Moore T.B., Martinez C., Lugt M.T.V., Leiding J.W., Torgerson T.R., Pai S-Y., Pulsipher M.A., Notarangelo L.D., Puck J., Dvorak C.C., Haddad E., Cowan M., and Heimall J. (2022). 437 - A primary immune deficiency treatment consortium (PIDTC) study of chronic and late onset medical complications after initial hematopoietic cell transplantation (HCT) for severe combined immunodeficiency disease (SCID). Trans. Cell. Therapy, 28(3): S339–S340.
Titman P., Pink E., Skucek E., O’Hanlon K., Cole T.J., Gaspar J., and Gaspar H.B. 2008. Cognitive and behavioral abnormalities in children after hematopoietic stem cell transplantation for severe congenital immunodeficiencies blood. J. Am. Soc. Hematol. 112(9): 3907–3913.
Lin M., Epport K., Azen C., Parkman R., Kohn D.B., and Shah A.J. 2009. Long-term neurocognitive function of pediatric patients with severe combined immune deficiency (SCID): pre-and post-hematopoietic stem cell transplant (HSCT). J. Clin. Immunol. 29: 231–237.
Cool V.A. 1996. Long-term neuropsychological risks in pediatric bone marrow transplant: what do we know? Bone Marrow Trans. 18 Suppl 3: S45–9.
Kane L., Gennery A.R., Crooks B.N.A., Flood T., Abinun M., and Cant A. 2001. Neonatal bone marrow transplantation for severe combined immunodeficiency. Arch. Dis. Child. 85: F110–F113.
Skucek E., Butler S., Gaspar H.B., and Titman P. 2011. Social outcome in children treated by haematopoietic cell transplant for congenital immunodeficiency. Bone Marrow Trans. 46(10): 1314–1320.
Reynolds E., Blanchard S., Jalazo E., Chakraborty P., and Bailey D.B. (2023). Newborn screening conditions: Early intervention and probability of developmental delay. J. Develop. Behav. Pediat. 44(5): e379–e387.
Information & Authors
Information
Published In
LymphoSign Journal
Volume 10 • Number 4 • December 2023
Pages: 66 - 70
History
Received: 17 October 2023
Accepted: 8 November 2023
Version of record online: 10 January 2024
Copyright
© 2023.
Authors
Metrics & Citations
Metrics
Other Metrics
Citations
Cite As
AngelaHu, OmarAlmatrafi, Vy HDKim, DonnaWall, and RaeBrager. 2023. Neurodevelopmental outcomes in two cases of artemis deficiency. LymphoSign Journal.
10(4): 66-70. https://doi.org/10.14785/lymphosign-2023-0011
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
There are no citations for this item
View Options
Get Access
Login options
Check if you access through your login credentials or your institution to get full access on this article.
